A new federal ruling means that patients will no longer have access to cheaper versions of Eli Lilly weight loss and diabetes ...

(Bloomberg) -- Eli Lilly & Co.’s diabetes and weight-loss drugs Mounjaro and ... The FDA said in October that there was no longer a shortage of Lilly’s drugs and that making copies must ...

The Food and Drug Administration (FDA) recently removed Eli Lily's weight-loss drug from its shortage list ... brand names Mounjaro and Zepbound, is no longer in short supply, but it means ...

Following a similar decision in case the trade group Outsourcing Facilities Association brought against FDA over its decision ...

Many compounding pharmacies are no longer allowed to make cheaper versions of semaglutide and other GLP-1 drugs. A doctor ...

Some of the bankrupt company’s closest rivals, newer telehealth firms, face a new challenge of their own as federal ...

Eli Lilly is ... to cut prescription drug prices in the US to the level paid by other comparable countries. Shares in Eli ...

Drugmaker Eli Lilly ... a huge trend in weight loss drugs. And orforglipron looks like it could be a game-changer, driving even more growth for Lilly. Geoffrey Seiler has no position in any ...

Could the long-running obesity drugs leadership anchored by the Denmark-headquartered Novo Nordisk (NVO) be finally coming to an end? While arch rival Eli Lilly ... its oral weight loss pill ...

Wegovy and Zepbound are part of a wave of obesity medications known as GLP-1 receptor agonists that have soared in popularity due to the amount of weight people lose while taking the injections.

Big Pharma has put a Houston pharmacy squarely in the crosshairs of its quest to weed out copycat versions of wildly popular diabetes and weight loss drugs. Eli Lilly, the maker of the diabetes ...